GSK 2849466

Drug Profile

GSK 2849466

Alternative Names: GSK2849466

Latest Information Update: 12 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cachexia; Heart failure

Most Recent Events

  • 23 Jun 2014 Adverse events and pharmacokinetics data from a phase I trial in Healthy volunteers presented at the Joint Meeting of the 16th International Congress of Endocrinology and the 96th Annual Meeting of the Endocrine Society (ICE/ENDO-2014)
  • 01 Feb 2014 Discontinued - Phase-I for Cachexia (In volunteers) in USA (PO) (GlaxoSmithKline pipeline, February 2014)
  • 01 Feb 2014 Discontinued - Phase-I for Heart failure in USA (PO) (GlaxoSmithKline pipeline, February 2014)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top